Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio

The use of immune checkpoint inhibitors (ICIs) has provided overall survival (OS) benefits in patients with treatment-naïve advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, studies comparing ICIs monotherapy with combination therapy either with chemotherapy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Jeng-Shiuan, Wei, Sheng-Huan, Chen, Chian-Wei, Yang, Szu-Chun, Tseng, Yau-Lin, Su, Po-Lan, Lin, Chien-Chung, Su, Wu-Chou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694359/
https://www.ncbi.nlm.nih.gov/pubmed/36422537
http://dx.doi.org/10.3390/ph15111407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694359/
https://www.ncbi.nlm.nih.gov/pubmed/36422537
http://dx.doi.org/10.3390/ph15111407

Ejemplares similares